Overview

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Status:
Terminated

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

This study will compare the anti-tumor efficacy of apricoxib and lapatinib/capecitabine with placebo and lapatinib/capecitabine as measured by time to disease progression and evaluate urinary PGE-M measurements or baseline COX-2 expression in tumor tissue by IHC as a surrogate selection criterion for patients who will benefit from future treatment with apricoxib.

Phase:

Phase 2

Details

Lead Sponsor:

Tragara Pharmaceuticals, Inc.

Treatments:

Capecitabine
Lapatinib